Unknown PHASE4 INTERVENTIONAL 1-arm NCT01584687

mRNA Expression as a Biomarker of Omalizumab Response

mRNA Expression as a Biomarker of Xolair (Omalizumab) Response

Sponsor: Instituto de Investigação em Imunologia

Conditions Asthma

Interventions Omalizumab

Updated 5 times since 2017 Last updated: Apr 24, 2012 Started: Jun 30, 2012 Primary completion: Dec 31, 2012 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Asthma and is currently ongoing. Instituto de Investigação em Imunologia leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Instituto de Investigação em Imunologia

Data source: Instituto de Investigação em Imunologia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.